Investor Relations

Cytokinetics is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Our development efforts are directed to advancing the movement of multiple drug candidates through clinical trials to demonstrate proof-of-concept in humans, specifically in the areas of heart failure and cancer. Details >>

Stock Quote
CYTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.87
Change (%) Stock is Up 0.02 (0.70%)
Volume64,349
Market Cap$141,907,150
Shares Outstanding49,445,000
Data as of 01/05/09 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsDetails >>
DateTitle 
12/23/08Cytokinetics Retains Development and Commercialization Rights to Ispinesib and SB-743921Printer Friendly Version
12/18/08Cytokinetics Announces Phase IIa Clinical Trial Results Relating to CK-1827452 in Patients With Ischemic Cardiomyopathy and AnginaPrinter Friendly Version
12/12/08Cytokinetics Announces Clinical and Preclinical Data Regarding Ispinesib Presented at the 31st Annual San Antonio Breast Cancer SymposiumPrinter Friendly Version
12/08/08Cytokinetics Announces Clinical Trial Data Regarding SB-743921 Presented at the 2008 Annual Meeting of American Society of HematologyPrinter Friendly Version
Upcoming EventsDetails >>
There are currently no events scheduled.
Featured ReportDetails >>
There are currently no items available.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Print PagePrint Page  |    Email PageEmail Page  |   Email AlertsEmail Alerts  |   IR ContactsIR Contacts